市況1 (2019/10/17 07:53:18)

【4565】そーせいG 492【Novartis Q3 2019 Results: 10/22】 |5ちゃんねる|山師さん@トレード中

BB2C Twincle Mate

 続きを見る。討論に参加する
速報  実況  市況

市況1

1 山師さん@トレード中2019/10/08(火) 07:28:42.35 ID:MA3MijZ8a
※前スレ
【4565】そーせいG 491【ERS International Congress 2019: 9/28-10/2】
https://hayabusa9.5ch.net/test/read.cgi/livemarket1/1569233434


2 山師さん@トレード中2019/10/08(火) 07:30:02.83 ID:MA3MijZ8a
Events;
・・・
※BioJapan2019:JITSUBO出展:最先端ペプチド合成技術、Molecular Hivingの最新情報を紹介。(10/9-11)
※OTS 2019: "Late Breaking Talk: Activation of CEBPA in Myeloid Cells by saRNA in HCC Patients: The Emergence of an Immunomodulatory Switch for Anti-Cancer Therapy": Nagy Habib. (10/16 16.25-16.40Presenting)
※Novartis Q3 2019 Results. (10/22)
※AstraZeneca Q3 2019 Results. (10/24)
※AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics: "Identification of Small Activating RNAs that can Upregulate Immune Activation Tagets for Cancer Immunotherapy": David Blakey, MiNA Therapeutics. (10/2912:30 Presenting)
※Medicinal Chemistry & Protein Degradation Summit: "RI Revitalises Drug Discovery & Drives AI": Jonthan Mason, Sosei Heptares. (10/28 15:00-16:00 Presenting)
※ERNEST First Meeting GPCR Pharmacology: Activation, Signalling and Drug Design: Invited Speakers: Chris Tate (MRC); Chris De Graaf (Sosei Heptares). Meeting Sponsored: Sosei Heptares. (10/28-30)


3 山師さん@トレード中2019/10/08(火) 07:30:43.43 ID:MA3MijZ8a
※DIA Oligonucleotide-Based Therapeutics Conference: "MTL-CEBPA, The First Small Activating RNA Therapy in Clinical Development": Nagy Habib, MiNA Therapeutics. (10/29 11:30-12:00 Presenting)
※PfizerQ3 2019 Results. (10/29)
※MorphoSys Q3 2019 Interim Statement. (10/29)
※Allergan Q3 2019 Results. (10/30 Projected)
※武田薬品工業2019年度第2四半期決算(10/31)
※第一三共2020年3月期第2四半期決算(10/31)
※Protein Structure Determination in Industry Meeting (PSDI 2019): Keynote Lecture: "Future Prospects of CryoEM": Richard Henderson, MRC-LMB. (11/4 14:00-14:45 Presenting)
※Protein Structure Determination in Industry Meeting (PSDI 2019): "Expanding the Scope of GPCR Structure-Based Drug Design with CryoEM": Stacey Southall, Sosei Heptares. (11/4 16:30-16:55 Presenting)


4 山師さん@トレード中2019/10/08(火) 07:31:42.02 ID:MA3MijZ8a
※ペプチドリーム2019年6月期第1四半期決算(11/7)
※Sosei Group 2019年12月期第3四半期決算発表(11/12)
※AACR Tumor Immunology and Immunotherapy: MiNA Therapeutics. (11/17-20)
※Clinical Trials Europe 2019: "CASE STUDY Magnetic Resonance Imaging Biomarkers in Early Phase Clinical Development: from Patient Selection to Proof of Mechanism": Geor Bakker, Sosei Heptares. (11/20 9:30-10:00 Presenting)
※Clinical Trials Europe 2019: Early Phase Clinical Development Round Table Session: "Table 1: Is biomarker driven early clinical development achieving critical go/no go decisions faster?" Pradeep Nathan, Sosei Heptares. (11/20 16:30)
※HBA London Presents Event "Understanding Mindfulness and Compassion: a Cognitive Neuroscience approach" Location: Sosei Heptares Steinmetz Building, Granta Park. (11/27 18:00-20:00)
※World BI DDIP (Drug Discovery Innovation Program) Conference 2019: Jonthan Mason, Sosei Heptares. (11/28-29)
・・・


5 山師さん@トレード中2019/10/08(火) 07:36:30.64 ID:MA3MijZ8a
・・・


 続きを見る。
勢い順